MAP2K1 and oral cavity cancer: Here, we characterized the anti-tumor and immune effects of rapamycin, an FDA-approved inhibitor of mTOR signaling, and an investigational MEK1/2 inhibitor PD0325901 in these syngeneic MOC1 and 2 murine models of Ras-mutant oral cavity cancer.